Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study

Cancer

Volumn 119, Issue 19, 2013, Pages 3570-3577

  Argyriou, Andreas A ^a,b   Cavaletti, Guido ^c   Antonacopoulou, Anna ^b   Genazzani, Armando A ^d   Briani, Chiara ^e   Bruna, Jordi ^f   Terrazzino, Salvatore ^d   Velasco, Roser ^f   Alberti, Paola ^c   Campagnolo, Marta ^e   Lonardi, Sara ^g   Cortinovis, Diego ^h   Cazzaniga, Marina ^h   Santos, Cristina ^f   Psaromyalou, Aikaterini ^b   Angelopoulou, Aikaterini ^b   Kalofonos, Haralabos P ^b  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

Author keywords

biomarkers; chemotherapy induced peripheral neuropathy; genotyping; neurotoxicity; oxaliplatin; SCNA

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8;

ADULT; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COLORECTAL CANCER; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GENETIC VARIABILITY; HUMAN; HYDROLYSIS KINETICS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SCN10A GENE; SCN4A GENE; SCN9A GENE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TOTAL NEUROPATHY SCORE;

BIOMARKERS; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; GENOTYPING; NEUROTOXICITY; OXALIPLATIN; SCNA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; INCIDENCE; LEUCOVORIN; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84884902436     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28234     Document Type: Article

References (30)

1. Kalofonos HP, Aravantinos G, Kosmidis P, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol. 2005; 16: 869-877.
2. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012; 23: 2479-2516.
3. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP,. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008; 34: 368-377.
4. Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP,. Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON. 2010; 15: 435-446.
5. Cavaletti G, Alberti P, Marmiroli P,. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011; 12: 1151-1161.
6. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G,. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012; 82: 51-77.
7. Antonacopoulou AG, Argyriou AA, Scopa CD, et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol. 2010; 17: 963-968.
8. Catterall WA,. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000; 26: 13-25.
9. Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999; 2: 541-548.
10. Yu FH, Catterall WA,. Overview of the voltage-gated sodium channel family. Genome Biol. 2003; 4: 207.
11. Catterall WA, Goldin AL, Waxman SG,; International Union of Pharmacology. International Union of Pharmacology. XXXIX. Compendium of voltage-gated ion channels: sodium channels. Pharmacol Rev. 2003; 55: 575-578.
12. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC,. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005; 32: 51-60.
13. Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol. 2012; 23: 3116-3122.
14. Cavaletti G, Cornblath DR, Merkies IS, et al. The CI-PeriNomS Group. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013; 24: 454-462.
15. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013; 119: 438-444.
16. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947.
17. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22: 2084-2091.
18. Pfeufer A, van Noord C, Marciante KD, et al. Genome-wide association study of PR interval. Nat Genet. 2010; 42: 153-159.
19. Reimann F, Cox JJ, Belfer I, et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A. 2010; 107: 5148-5153.
20. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E,. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001; 85: 2293-2297.
21. Grisold W, Cavaletti G, Windebank AJ,. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012; 14 (suppl 4): iv45-iv54.
22. Burge JA, Hanna MG,. Novel insights into the pathomechanisms of skeletal muscle channelopathies. Curr Neurol Neurosci Rep. 2012; 12: 62-69.
23. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012; 109: 6704-6709.
24. Hogenauer C, Santa Ana CA, Porter JL, et al. Active intestinal chloride secretion in human carriers of cystic fibrosis mutations: an evaluation of the hypothesis that heterozygotes have subnormal active intestinal chloride secretion. Am J Hum Genet. 2000; 67: 1422-1427.
25. Pace BS, Ofori-Acquah SF, Peterson KR,. Sickle cell disease: genetics, cellular and molecular mechanisms, and therapies. Anemia. 2012; 2012: 143594.
26. Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC,. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009; 27: 1243-1249.
27. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC,. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009; 132 (pt 10): 2712-2723.
28. Adelsberger H, Quasthoff S, Grosskreutz J, et al. Alteration of sodium channel inactivation kinetics on rat sural nerve by the chemotherapeutic agent oxaliplatin. Biol Chem. 1999; 380S: 123.
29. Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012; 118: 2828-2836.
30. Cecchin E, D'Andrea M, Lonardi S, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin(FOLFOX4) regimen [published online ahead of print August 7, 2012 ]. Pharmacogenomics J. doi: 10.1038/tpj.2012.31.